Table 1:
Baseline characteristics
| Average (range) | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | |
|---|---|---|---|---|---|---|
| Age (years) | 40.8 (35-50) | 37 | 35 | 43 | 39 | 50 |
| Sex | Male (4) | Male | Male | Female | Male | Male |
| Ethnicity | Caucasian (4) African American (1) |
Caucasian | Caucasian | Caucasian | African American | Caucasian |
| Months since sarcoid diagnosis | 33 (9-60) | 48 | 24 | 9 | 60 | 24 |
| WASOG: Highly probably (HP) At least probably (ALP) Possible (P) |
Lung: HP (4); ALP (4) Skin: ALP (2) Extra-thoracic lymph nodes: ALP (2) Bone-Joint: P (1) Spleen: ALP (1) Calcium-Vitamin D: ALP (1) Nervous system: HP (1) |
Lung: ALP | Lung: HP; ALP | Lung: HP; ALP | Lung: HP Extra-thoracic lymph nodes: ALP Skin: ALP Joint: P |
Lung: HP; ALP Skin: ALP Bone-Joint: P Spleen: ALP Calcium-Vitamin D: ALP Nervous system: HP |
| Prednisone dose (mg/day) | 19 (15-25) | 20 | 25 | 15 | 20 | 15 |
| Duration of steroid use prior to trial (months) | 14.8 (7-36) | 36 | 12 | 10 | 7 | 9 |
| DMARDs tried (outcome) | MTX (2) MMF (1) |
MTX 10 mg/week x 2 months (no benefit) | None | None | None | MTX (intolerance), MMF (no benefit) |
| Pulmonary sarcoidosis characteristics | ILD (1) Nodules (4) Hilar/mediastinal LAD (3) |
ILD | Nodules, hilar/mediastinal LAD | Nodules, hilar/mediastinal LAD | Nodules, hilar/mediastinal LAD | Nodules |
| Tissue confirmation | Lung biopsy (2) Lymph node (2) Skin (1) |
EBUS left lower lobe | EBUS right hilar lymph node | EBUS right middle lobe | Skin punch biopsy | Excisional biopsy iliac lymph node |
| Pulmonary function (% predicted) | FEV1: 78.4 (28-113) FVC: 86.6 (55-122) DLCO: 89.2 (68-105) |
FEV1: 28 FVC: 57 DLCO: 95 |
FEV1: 88 FVC: 91 DLCO: 105 |
FEV1: 103 FVC: 108 DLCO: 100 |
FEV1: 113 FVC: 122 DLCO: 68 |
FEV1: 60 FVC: 55 DLCO: 78 |
Baseline characteristics are shown as an average for all five patients, and individual data for each patient is shown. DMARD: disease modifying anti-rheumatic drug, MTX: methotrexate, MMF: mycophenolate mofetil, ILD: interstitial lung disease, LAD: lymphadenopathy, DMARDs: disease modifying antirheumatic drugs; FEV1: forced expiratory volume in 1 second, FVC: forced vital capacity, DLCO: diffusion capacity for carbon monoxide, EBUS: endobronchial ultrasound